Blood cancer, Acute myeloid leukemia, Cancer
KURAKura OncologyCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Ziftomenib + venetoclax + azacitidine in Blood cancer, Acute myeloid leukemia, Cancer. The expected timing is based on the latest available company guidance and may change.
KOMET-017-NIC trial. 2/26/2025- Initiate trial in H2 2025. 9/29/25- First patient dosed. 11/04/25:- Phase 3 KOMET-017 frontline non-intensive cohort first patient dosing reiterated; trials accelerating. 01/11/26:- Plan to advance KOMET-017-NIC Phase 3 enrollment in newly diagnosed AML throughout 2026. 03/05/26:- KOMET-017 non-intensive frontline AML enrollment ongoing; first pivotal Phase 3 topline results anticipated in 2028. 05/12/26:- KOMET-017 enrolling; EHA abstract online May 12, 2026. Accelerated FDA review potential in 2028. 05/12/26:- KOMET-017-NIC Phase 3 global site activation and enrollment ongoing with strong early progress; topline results still expected 2028. 08/12/26:- KOMET-017 non-intensive cohort enrollment continues. First pivotal Phase 3 topline results are expected in 2028.
Verification
Confirm timing and program details against the company announcement or filing.